Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which treatment works best for Dupuytren's? major trial aims to find out

NCT ID NCT03192020

Disease control Sponsor: Tampere University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares three treatments for Dupuytren's contracture, a hand condition that causes fingers to bend inward. The treatments are needle fasciotomy (a quick in-office procedure), collagenase injection (a drug that breaks up the tight cord), and surgery (limited fasciectomy). The trial involves 302 adults with at least 20 degrees of finger bending. The goal is to see which approach is most cost-effective and provides the best long-term results.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Collagenase Clostridium Histolyticum (CCH) injection
What this could lead to
If this trial succeeds, it could identify the most effective and cost-efficient treatment for Dupuytren's contracture, helping patients and doctors choose the best option.
What could go wrong
This is a phase 4 trial, but results are still pending. The best treatment may depend on individual patient factors, and not all patients may respond equally to each approach.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

302 people

The number who actually took part.

Started

Sep 2017

Expected to finish

May 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * patients with ≥20° passive extension deficit in metacarpophalangeal (MPJ) or proximal interphalangeal joint (PIPJ), or TPED ≥30° in MPJ and PIPJ of finger/fingers II-V * age \> 18 years * palpable cord * provision of informed consent * ability to fill the Finnish versions of questionnaires. Exclusion Criteria: * recurrent contracture in the finger to be treated * neurologic condition causing the loss of function of the finger to be treated * contraindication for collagenase clostridium histolyticym (Xiapex/Xiaflex ®) * pregnant or breast feeding * total passive extension deficit \> 135° (Tubiana stage 4) in finger to be treated * rheumatoid arthritis * previous fracture in finger to be treated, which affects range of motion of MPJ or PIPJ * age \> 80 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dupuytren contracture are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

connective tissue disorder Contracture palmar fibromatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dupuytren contracture

Contacts and locations

Locations

  • Central Hospital of Central Finland

    Jyväskylä, Central Finland, 40620, Finland

  • Helsinki University hospital

    Helsinki, Uusimaa, 00029, Finland

  • Kuopio University hospital

    Kuopio, Northern Savonia, 70029, Finland

  • Oulu University hospital

    Oulu, North Ostrobothnia, 90220, Finland

  • Tampere University Hospital

    Tampere, Pirkanmaa, 33521, Finland

  • Turku University Hospital

    Turku, Southwest Finland, 20521, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.